Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: Which is suitable for on-demand therapy?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 9, 2003, Pages 1034-1038

  Inamori, Masahiko ^a,b   Togawa, Jun Ichi ^a   Takahashi, Hirokazu ^a   Yoneda, Masato ^a   Fujisawa, Nobutaka ^a   Iwasaki, Tomoyuki ^a   Ozawa, Yutaka ^a   Kikuchi, Taisuke ^a   Muramatsu, Kenichi ^a   Chiguchi, Gaku ^a   Matsumoto, Shuhei ^a   Kawamura, Harunobu ^a   Abe, Yasunobu ^a   Kirikoshi, Hiroyuki ^a   Kobayashi, Noritoshi ^a   Sakaguchi, Takashi ^a   Takamura, Tomoo ^a   Nakajima, Atsushi ^a   Ueno, Norio ^a   Sekihara, Hisahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Omeprazole; On demand therapy; Proton pump inhibitor; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG METABOLISM; GENOTYPE; HEARTBURN; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PH;

EID: 10744221112     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03126.x     Document Type: Article

References (32)

1. Endo M, Kobayashi S, Suzuki H et al. Diagnosis of early esophageal cancer. Endoscopy 1971; 2: 61-6.
2. Furukawa N, Iwakiri R, Koyama T et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J. Gastroenterol. 1999; 34: 441-4.
3. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. 1996; 31: 386-406.
4. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
5. Marchildon PA, Ciota LM, Zamaniyan FZ, Peacock JS, Graham DY. Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection. J. Clin. Microbiol. 1996; 34: 1147-52.
6. Evans DJ Jr., Evans DG, Graham DY, Klein PD. A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology 1989; 96: 1004-8.
7. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996; 60: 661-6.
8. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994; 269: 15419-22.
9. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994; 46: 594-8.
10. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24 h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-89.
11. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 2001; 15: 1929-37.
12. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002; 16: 1811-7.
13. Verdu EF, Armstrong D, Idstrom JP et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743-8.
14. Verdu EF, Armstrong D, Fraser R et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
15. Labenz J, Tillenburg B, Peitz U et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
16. Verdu EF, Armstrong D, Idstrom JP et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand. J. Gastroenterol. 1996; 31: 1151-6.
17. Cave DR, Vargas M. Effect of a Campylobacter pylori protein on acid secretion by parietal cells. Lancet 1989; 2: 187-9.
18. Beil W, Birkholz C, Wagner S, Sewing KF. Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase. Gut 1994; 35: 1176-80.
19. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
20. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113 (Suppl. 6): S43-50.
21. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13.
22. Haruma K, Hamada H, Mihara M et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter 2000; 5: 24-9.
23. Ishizaki T, Horai Y, Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole (Review Article). Aliment. Pharmacol. Ther. 1999; 13 (Suppl. 3): 27-36.
24. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 1984; 36: 773-80.
25. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 1996; 31: 9-28.
26. Furuta T, Ohashi K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 1999; 65: 552-61.
27. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-46.
28. Cook DJ, Fuller HD, Guyatt GH et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N. Engl. J. Med. 1994; 330: 377-81.
29. Smythe MA, Zarowitz BJ. Changing perspectives of stress gastritis prophylaxis. Ann. Pharmacother. 1994; 28: 1073-85.
30. Stothert JC Jr, Dellinger EP, Simonowitz DA, Schilling JA. Gastric pH monitoring as a prognostic indicator for the prophylaxis of stress ulceration in the critically III. Am. J. Surg. 1980; 140: 761-3.
31. Watanabe Y, Tsumura H, Sasaki H, Morimoto T. The effects of intermittent and continuous intravenous infusion of famotidine on gastric acidity in patients with peptic ulcers. Clin. Ther. 1990; 12: 534-46.
32. Matthews HR. A proposed classification for hiatal hernia and gastroesophageal reflux. Dis. Esophagus 1996; 9: 1-3.